Compare ALLT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | STRO |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.0M | 381.1M |
| IPO Year | 2006 | 2018 |
| Metric | ALLT | STRO |
|---|---|---|
| Price | $7.73 | $21.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $12.40 | ★ $31.33 |
| AVG Volume (30 Days) | 243.1K | ★ 305.4K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | $15.84 | N/A |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.12 | $0.72 |
| 52 Week High | $11.92 | $43.85 |
| Indicator | ALLT | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 40.80 |
| Support Level | $7.41 | $18.74 |
| Resistance Level | $8.51 | $27.16 |
| Average True Range (ATR) | 0.37 | 1.97 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 28.92 | 46.78 |
Allot Ltd is a provider of security and network intelligence solutions for mobile, fixed, and cloud service providers, as well as enterprises. It offers network-based security solutions such as mobile security, DDoS protection, and IoT security, along with network analytics and traffic management. It focuses on expanding its Security-as-a-Service (SECaaS) offerings through the Allot Secure product family, which delivers unified protection for consumers and SMBs across mobile, fixed, and 5G networks. Its Allot Smart solutions enable service providers to analyze and manage network data, optimize performance, reduce costs, and enhance user experience. It has a customer base in Europe, which generates maximum revenue, as well as in Asia and Oceania, the Americas, the Middle East, and Africa.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.